市場調査レポート

商品コード

1397033

医薬坐剤市場：タイプ別、基剤別、流通チャネル別、エンドユーザー別、処方タイプ別：2023年～2032年の世界機会分析と産業予測

Pharmaceutical Suppositories Market By Type, By Base, By Distribution Channel, By End User, By Prescription Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年10月31日 | 発行: Allied Market Research

| ページ情報: 英文 377 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

医薬坐剤市場は、2022年に16億646万米ドルと評価され、2023年から2032年までのCAGRは5.7%で、2032年には28億205万米ドルに達すると予測されています。

坐薬は、口以外の体腔に挿入するために正確に設計された固形剤形です。直腸、腟、尿道などに入れることができます。これらの薬剤は、挿入後、腔液中で溶けるか、溶解して薬剤が放出されるように設計されています。挿入部位によって、坐剤は直腸坐剤、膣坐剤、尿道坐剤に分けられます。坐薬は現場での作用に有用性があります。薬物を代謝から救う初回通過効果を省くことができます。苦い薬物や不快な薬物の場合、坐薬は薬物送達の選択肢として使用されます。小児科では、坐薬はしばしば便秘に似た症状の治療に使用されます。しかし、使用部位に粘膜刺激が生じる可能性があり、そのために使用が制限されることがあります。

坐薬の使用を必要とする慢性疾患の有病率の増加は、医薬坐剤市場の重要な促進要因です。炎症性腸疾患、痔、特定のがんなどの慢性疾患は、局所的なドラッグデリバリーの恩恵を受けることが多く、全身的な副作用が軽減されます。ライフスタイルの変化や人口の高齢化など様々な要因により、これらの症状がより一般的になるにつれ、坐薬をベースとした治療薬への需要が高まる。例えば、National Library of Medicineに掲載された論文によると、カナダでは32万人が炎症性腸疾患（IBD）と共に生活しており、2035年までに人口の1.1％、47万人のカナダ人がIBDと共に生活すると予想されるなど、有病率は年間2.44％上昇すると予測されています。

この動向は製薬企業に大きな成長機会を提供し、新しい製剤の開拓や、慢性疾患を抱える人々のヘルスケアニーズに応える座薬市場の拡大につながります。

しかし、安定性や溶解性の問題から、すべての薬剤が坐薬を通じて効果的に送達されるわけではないため、薬剤の適合性には限界があり、市場成長の妨げとなっています。さらに、製造が複雑で特殊な設備や工程が必要なため、製造コストが上昇し、製造業者の数も制限されるため、市場へのアクセスや購入しやすさが制限されます。

医薬坐剤市場は、タイプ、ベース、流通チャネル、エンドユーザー、処方タイプ、地域に区分されます。タイプ別では、市場は直腸坐薬、膣坐薬、尿道坐薬に分けられます。基剤ベースでは、脂肪性基剤、水混和性基剤、乳化性基剤に分類されます。水混和性基剤はさらに、グリセロゼラチン基剤、石鹸グリセリン坐剤、ポリエチレングリコール基剤に区分されます。乳化性ベースはさらに、ウィテプゾール、マサエステリウム、マサポールに区分されます。

流通チャネル別では、市場は病院薬局、小売薬局、オンライン販売に分けられます。エンドユーザー別では、病院・診療所、在宅医療、介護施設に分類されます。処方タイプ別では、OTC坐薬と処方坐薬に二分されます。地域別では、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。医薬坐剤市場で事業を展開する主要企業には、Bayer AG、Bliss Gvs Pharma Ltd、Viatris Inc、Cadila Healthcare Ltd、Church &Dwight Co., Inc、Glenmark Pharmaceuticals Limited、Intas Pharmaceuticals Ltd、Novartis AG、Pfizer Inc.、Sanofi S.A.などがあります。

座薬はドラッグデリバリーの優れた代替手段となり、意識のない患者や現場での直接作用が望まれる場合に有用です。

高齢者人口の増加、世界の胃腸疾患の増加、子宮内疾患や様々な慢性疾患の増加、病院・診療所数の増加などの要因が、医薬坐剤市場の成長を促進すると予想されます。さらに、直腸坐薬の使用の増加と技術の進歩が市場の成長をさらに後押しします。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 座薬の使用を必要とする急性・慢性疾患の有病率の上昇
  - 老人人口の増加
  - 坐薬の使用に対する認識と教育への取り組みの増加
- 抑制要因
  - 製造の複雑さ
  - 薬物適合性の制限
- 機会
  - 坐薬の技術的進歩

第4章医薬坐剤市場：タイプ別

概要
直腸坐剤
膣坐剤
尿道坐剤

第5章医薬坐剤市場：基剤別

概要
脂肪塩基
水混和性基剤
- 水混和性基剤タイプ別医薬坐剤市場
乳化性基剤
- 乳化性基剤のタイプ別医薬坐剤市場

第6章医薬坐剤市場：流通チャネル別

概要
病院薬局
小売薬局
オンライン販売

第7章医薬坐剤市場：エンドユーザー別

概要
病院・診療所
在宅医療
介護施設

第8章医薬坐剤市場：処方タイプ別

概要
一般用医薬品
処方坐薬

第9章医薬坐剤市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第10章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第11章企業プロファイル

Bayer AG
Bliss GVS Pharma Ltd
Viatris Inc.
Church & Dwight Co. Inc.
Glenmark Pharmaceuticals Limited
Intas Pharmaceuticals Ltd.
Cadila Healthcare Ltd
Novartis AG
Pfizer Inc.
Sanofi S.A.

図表

LIST OF TABLES

TABLE 01. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 06. PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL WATER MISCIBLE BASE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 09. PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL EMULSIFYING BASES PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 11. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY REGION, 2022-2032 ($MILLION)
TABLE 18. PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY REGION, 2022-2032 ($MILLION)
TABLE 19. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 20. PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY REGION, 2022-2032 ($MILLION)
TABLE 21. PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 22. PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 34. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 36. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 38. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 39. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 41. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 44. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 46. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 49. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 50. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 51. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 52. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 55. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 57. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 60. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 61. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 62. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 65. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 66. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 67. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 70. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 72. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 75. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 76. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 77. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 80. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 82. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 84. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 85. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 86. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 88. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 91. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 92. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 93. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 96. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 97. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 98. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 100. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 101. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 102. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 103. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 104. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 105. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 106. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 107. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 108. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 109. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 110. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 113. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 114. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 116. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 117. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 118. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 119. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 120. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 121. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 122. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 123. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 124. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 125. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 126. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 127. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 128. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 129. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 130. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 131. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 132. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 133. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 134. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 135. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 136. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 137. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 138. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
TABLE 139. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 140. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 141. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 142. BAYER AG: KEY EXECUTIVES
TABLE 143. BAYER AG: COMPANY SNAPSHOT
TABLE 144. BAYER AG: PRODUCT SEGMENTS
TABLE 145. BAYER AG: PRODUCT PORTFOLIO
TABLE 146. BLISS GVS PHARMA LTD: KEY EXECUTIVES
TABLE 147. BLISS GVS PHARMA LTD: COMPANY SNAPSHOT
TABLE 148. BLISS GVS PHARMA LTD: PRODUCT SEGMENTS
TABLE 149. BLISS GVS PHARMA LTD: PRODUCT PORTFOLIO
TABLE 150. VIATRIS INC.: KEY EXECUTIVES
TABLE 151. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 152. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 153. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 154. CHURCH & DWIGHT CO. INC.: KEY EXECUTIVES
TABLE 155. CHURCH & DWIGHT CO. INC.: COMPANY SNAPSHOT
TABLE 156. CHURCH & DWIGHT CO. INC.: PRODUCT SEGMENTS
TABLE 157. CHURCH & DWIGHT CO. INC.: PRODUCT PORTFOLIO
TABLE 158. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 159. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 160. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 161. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 162. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES
TABLE 163. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 164. INTAS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
TABLE 165. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 166. CADILA HEALTHCARE LTD: KEY EXECUTIVES
TABLE 167. CADILA HEALTHCARE LTD: COMPANY SNAPSHOT
TABLE 168. CADILA HEALTHCARE LTD: PRODUCT SEGMENTS
TABLE 169. CADILA HEALTHCARE LTD: PRODUCT PORTFOLIO
TABLE 170. CADILA HEALTHCARE LTD: KEY STRATERGIES
TABLE 171. NOVARTIS AG: KEY EXECUTIVES
TABLE 172. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 173. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 174. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 175. PFIZER INC.: KEY EXECUTIVES
TABLE 176. PFIZER INC.: COMPANY SNAPSHOT
TABLE 177. PFIZER INC.: PRODUCT SEGMENTS
TABLE 178. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 179. SANOFI S.A.: KEY EXECUTIVES
TABLE 180. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 181. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 182. SANOFI S.A.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUPPOSITORIES MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2023-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 30. PHARMACEUTICAL SUPPOSITORIES MARKET BY REGION, 2022 AND 2032(%)
FIGURE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 32. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 33. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 34. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 35. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 36. UK PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 37. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 38. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 40. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 41. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 42. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 43. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 44. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 46. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 47. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 48. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 49. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
FIGURE 50. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 54. COMPETITIVE DASHBOARD
FIGURE 55. COMPETITIVE HEATMAP: PHARMACEUTICAL SUPPOSITORIES MARKET
FIGURE 56. TOP PLAYER POSITIONING, 2022
FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. BLISS GVS PHARMA LTD: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 61. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. CHURCH & DWIGHT CO. INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 64. CHURCH & DWIGHT CO. INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 66. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 67. CADILA HEALTHCARE LTD: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 68. CADILA HEALTHCARE LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 70. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 71. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 73. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 74. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 75. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 76. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 77. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A12350

The Pharmaceutical Suppositories Market was valued for $1,606.46 million in 2022 and is estimated to reach $2,802.05 million by 2032, exhibiting a CAGR of 5.7% from 2023 to 2032.

Suppositories are solid dosage forms of medication that are precisely designed for insertion into bodily cavities other than the mouth. They can be placed in the rectum, vaginal canal, or urethra. These items are designed to melt or dissolve in the cavity fluids after insertion, allowing the drug to be released. On the basis of the site of insertion, suppositories are divided into rectal suppository, vaginal suppository, and urethral suppository. Suppositories have usefulness in on-site action. It omits the first-pass effect which save drug from metabolism. In case of bitter and obnoxious drugs, suppositories are used as drug delivering option. In pediatrics, suppositories are often used to treat symptoms similar to constipation. However, there is a possibility of mucosal irritation at the site of use which may limit its usage.

The increase in prevalence of chronic diseases that necessitate the use of suppositories is a significant driver for the pharmaceutical suppositories market. Chronic conditions such as inflammatory bowel disease, hemorrhoids, and certain cancers often benefit from localized drug delivery, reducing systemic side effects. The demand for suppository-based treatments rises as these conditions become more common due to various factors such as lifestyle changes and aging populations. For instance, according to the article published in National Library of Medicine, stated that 320,000 people in Canada have been living with Inflammatory bowel disease (IBD), and the prevalence is forecasted to rise by 2.44% per year such 1.1% of the population, 470,000 Canadians, are anticipated to live with IBD by 2035.

This trend offers substantial growth opportunities for pharmaceutical companies, leading to the development of new formulations and expanding the market for suppository-based medications to meet the healthcare needs of individuals with chronic diseases.

However, limited drug compatibility hinders market growth as not all medications are effectively delivered through suppositories due to stability and solubility issues. In addition, manufacturing complexities, requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability.

The pharmaceutical suppositories market is segmented into type, base, distribution channel, end user, prescription type and region. On the basis of type, the market is divided into rectal suppositories, vaginal suppositories and urethral suppositories. On the basis of base, it is classified into fatty base, water miscible bases, and emulsifying bases. The water miscible bases are further segmented into glycero gelatin base, soap glycerin suppositories, and polyethylene glycol bases. The emulsifying bases are further segmented into witepsol, massa esterium, and massuppol.

On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online sales. On the basis of end user, it is classified into hospitals & clinics, home care and nursing home. On the basis of prescription type, it is bifurcated into OTC and prescribed suppositories. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The major players that operate in the pharmaceutical suppositories market include Bayer AG, Bliss Gvs Pharma Ltd, Viatris Inc, Cadila Healthcare Ltd, Church & Dwight Co., Inc., Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.

suppositories provide great alternative of drug delivery and can be useful in case of unconscious patients or where direct on-site action is desired.

The factors such as increased geriatric population, rise in number of gastro-intestinal diseases across the globe, rise in intra uterine diseases and various chronic diseases and rise in number of hospitals & clinics are expected to drive the growth of the pharmaceutical suppositories market. Moreover, the increase in use of rectal suppositories and technological advancements further boost the growth of the market.

In addition, North America is expected to witness the highest growth, in terms of revenue, owing to ongoing technological advancements, a well-established and advanced healthcare infrastructure, and adoption of suppositories for treatment by patients and healthcare providers. However, Asia-Pacific is anticipated to witness notable growth, owing to a rise in geriatric population and an increase in initiative to expand the healthcare facilities in the region, thus driving the growth of the market during the forecast period.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suppositories market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suppositories market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pharmaceutical suppositories market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pharmaceutical suppositories market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles

Key Market Segments

By Type

Rectal Suppositories
Vaginal Suppositories
Urethral Suppositories

By Base

Fatty Bases
Water Miscible Base
- Type
- Glycero Gelatin Base
- Soap Glycerin Suppositories
- Polyethylene Glycol Bases
Emulsifying Bases
- Type
- Witepsol
- Massa Esterium
- Massuppol

By End User

Hospitals and Clinics
Home Care
Nursing Home

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Sales

By Prescription Type

OTC
Prescribed Suppositories

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bayer AG
Church & Dwight Co. Inc.
Cadila Healthcare Ltd
Pfizer Inc.
Intas Pharmaceuticals Ltd.
Viatris Inc.
Novartis AG
Sanofi S.A.
Bliss GVS Pharma Ltd
Glenmark Pharmaceuticals Limited

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of acute & chronic disorders which require the use of suppository
  - 3.4.1.2. Increase in the geriatric population
  - 3.4.1.3. Increase in initiatives for awareness and education for use of suppositories
- 3.4.2. Restraints
  - 3.4.2.1. Manufacturing complexities
  - 3.4.2.2. Limited drug compatibility
- 3.4.3. Opportunities
  - 3.4.3.1. Technological advancements in suppositories

CHAPTER 4: PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Rectal Suppositories
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Vaginal Suppositories
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Urethral Suppositories
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Fatty Bases
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Water Miscible Base
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.3.4. Water Miscible Base Pharmaceutical Suppositories Market by Type
5.4. Emulsifying Bases
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.4.4. Emulsifying Bases Pharmaceutical Suppositories Market by Type

CHAPTER 6: PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Sales
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Hospitals and Clinics
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Home Care
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Nursing Home
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE

8.1. Overview
- 8.1.1. Market size and forecast
8.2. OTC
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by region
- 8.2.3. Market share analysis by country
8.3. Prescribed Suppositories
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by region
- 8.3.3. Market share analysis by country

CHAPTER 9: PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION

9.1. Overview
- 9.1.1. Market size and forecast By Region
9.2. North America
- 9.2.1. Key market trends, growth factors and opportunities
- 9.2.2. Market size and forecast, by Type
- 9.2.3. Market size and forecast, by Base
- 9.2.4. Market size and forecast, by Distribution Channel
- 9.2.5. Market size and forecast, by End User
- 9.2.6. Market size and forecast, by Prescription Type
- 9.2.7. Market size and forecast, by country
  - 9.2.7.1. U.S.
  - 9.2.7.1.1. Market size and forecast, by Type
  - 9.2.7.1.2. Market size and forecast, by Base
  - 9.2.7.1.3. Market size and forecast, by Distribution Channel
  - 9.2.7.1.4. Market size and forecast, by End User
  - 9.2.7.1.5. Market size and forecast, by Prescription Type
  - 9.2.7.2. Canada
  - 9.2.7.2.1. Market size and forecast, by Type
  - 9.2.7.2.2. Market size and forecast, by Base
  - 9.2.7.2.3. Market size and forecast, by Distribution Channel
  - 9.2.7.2.4. Market size and forecast, by End User
  - 9.2.7.2.5. Market size and forecast, by Prescription Type
  - 9.2.7.3. Mexico
  - 9.2.7.3.1. Market size and forecast, by Type
  - 9.2.7.3.2. Market size and forecast, by Base
  - 9.2.7.3.3. Market size and forecast, by Distribution Channel
  - 9.2.7.3.4. Market size and forecast, by End User
  - 9.2.7.3.5. Market size and forecast, by Prescription Type
9.3. Europe
- 9.3.1. Key market trends, growth factors and opportunities
- 9.3.2. Market size and forecast, by Type
- 9.3.3. Market size and forecast, by Base
- 9.3.4. Market size and forecast, by Distribution Channel
- 9.3.5. Market size and forecast, by End User
- 9.3.6. Market size and forecast, by Prescription Type
- 9.3.7. Market size and forecast, by country
  - 9.3.7.1. Germany
  - 9.3.7.1.1. Market size and forecast, by Type
  - 9.3.7.1.2. Market size and forecast, by Base
  - 9.3.7.1.3. Market size and forecast, by Distribution Channel
  - 9.3.7.1.4. Market size and forecast, by End User
  - 9.3.7.1.5. Market size and forecast, by Prescription Type
  - 9.3.7.2. France
  - 9.3.7.2.1. Market size and forecast, by Type
  - 9.3.7.2.2. Market size and forecast, by Base
  - 9.3.7.2.3. Market size and forecast, by Distribution Channel
  - 9.3.7.2.4. Market size and forecast, by End User
  - 9.3.7.2.5. Market size and forecast, by Prescription Type
  - 9.3.7.3. UK
  - 9.3.7.3.1. Market size and forecast, by Type
  - 9.3.7.3.2. Market size and forecast, by Base
  - 9.3.7.3.3. Market size and forecast, by Distribution Channel
  - 9.3.7.3.4. Market size and forecast, by End User
  - 9.3.7.3.5. Market size and forecast, by Prescription Type
  - 9.3.7.4. Italy
  - 9.3.7.4.1. Market size and forecast, by Type
  - 9.3.7.4.2. Market size and forecast, by Base
  - 9.3.7.4.3. Market size and forecast, by Distribution Channel
  - 9.3.7.4.4. Market size and forecast, by End User
  - 9.3.7.4.5. Market size and forecast, by Prescription Type
  - 9.3.7.5. Spain
  - 9.3.7.5.1. Market size and forecast, by Type
  - 9.3.7.5.2. Market size and forecast, by Base
  - 9.3.7.5.3. Market size and forecast, by Distribution Channel
  - 9.3.7.5.4. Market size and forecast, by End User
  - 9.3.7.5.5. Market size and forecast, by Prescription Type
  - 9.3.7.6. Rest of Europe
  - 9.3.7.6.1. Market size and forecast, by Type
  - 9.3.7.6.2. Market size and forecast, by Base
  - 9.3.7.6.3. Market size and forecast, by Distribution Channel
  - 9.3.7.6.4. Market size and forecast, by End User
  - 9.3.7.6.5. Market size and forecast, by Prescription Type
9.4. Asia-Pacific
- 9.4.1. Key market trends, growth factors and opportunities
- 9.4.2. Market size and forecast, by Type
- 9.4.3. Market size and forecast, by Base
- 9.4.4. Market size and forecast, by Distribution Channel
- 9.4.5. Market size and forecast, by End User
- 9.4.6. Market size and forecast, by Prescription Type
- 9.4.7. Market size and forecast, by country
  - 9.4.7.1. Japan
  - 9.4.7.1.1. Market size and forecast, by Type
  - 9.4.7.1.2. Market size and forecast, by Base
  - 9.4.7.1.3. Market size and forecast, by Distribution Channel
  - 9.4.7.1.4. Market size and forecast, by End User
  - 9.4.7.1.5. Market size and forecast, by Prescription Type
  - 9.4.7.2. China
  - 9.4.7.2.1. Market size and forecast, by Type
  - 9.4.7.2.2. Market size and forecast, by Base
  - 9.4.7.2.3. Market size and forecast, by Distribution Channel
  - 9.4.7.2.4. Market size and forecast, by End User
  - 9.4.7.2.5. Market size and forecast, by Prescription Type
  - 9.4.7.3. Australia
  - 9.4.7.3.1. Market size and forecast, by Type
  - 9.4.7.3.2. Market size and forecast, by Base
  - 9.4.7.3.3. Market size and forecast, by Distribution Channel
  - 9.4.7.3.4. Market size and forecast, by End User
  - 9.4.7.3.5. Market size and forecast, by Prescription Type
  - 9.4.7.4. India
  - 9.4.7.4.1. Market size and forecast, by Type
  - 9.4.7.4.2. Market size and forecast, by Base
  - 9.4.7.4.3. Market size and forecast, by Distribution Channel
  - 9.4.7.4.4. Market size and forecast, by End User
  - 9.4.7.4.5. Market size and forecast, by Prescription Type
  - 9.4.7.5. South Korea
  - 9.4.7.5.1. Market size and forecast, by Type
  - 9.4.7.5.2. Market size and forecast, by Base
  - 9.4.7.5.3. Market size and forecast, by Distribution Channel
  - 9.4.7.5.4. Market size and forecast, by End User
  - 9.4.7.5.5. Market size and forecast, by Prescription Type
  - 9.4.7.6. Rest of Asia-Pacific
  - 9.4.7.6.1. Market size and forecast, by Type
  - 9.4.7.6.2. Market size and forecast, by Base
  - 9.4.7.6.3. Market size and forecast, by Distribution Channel
  - 9.4.7.6.4. Market size and forecast, by End User
  - 9.4.7.6.5. Market size and forecast, by Prescription Type
9.5. LAMEA
- 9.5.1. Key market trends, growth factors and opportunities
- 9.5.2. Market size and forecast, by Type
- 9.5.3. Market size and forecast, by Base
- 9.5.4. Market size and forecast, by Distribution Channel
- 9.5.5. Market size and forecast, by End User
- 9.5.6. Market size and forecast, by Prescription Type
- 9.5.7. Market size and forecast, by country
  - 9.5.7.1. Brazil
  - 9.5.7.1.1. Market size and forecast, by Type
  - 9.5.7.1.2. Market size and forecast, by Base
  - 9.5.7.1.3. Market size and forecast, by Distribution Channel
  - 9.5.7.1.4. Market size and forecast, by End User
  - 9.5.7.1.5. Market size and forecast, by Prescription Type
  - 9.5.7.2. Saudi Arabia
  - 9.5.7.2.1. Market size and forecast, by Type
  - 9.5.7.2.2. Market size and forecast, by Base
  - 9.5.7.2.3. Market size and forecast, by Distribution Channel
  - 9.5.7.2.4. Market size and forecast, by End User
  - 9.5.7.2.5. Market size and forecast, by Prescription Type
  - 9.5.7.3. South Africa
  - 9.5.7.3.1. Market size and forecast, by Type
  - 9.5.7.3.2. Market size and forecast, by Base
  - 9.5.7.3.3. Market size and forecast, by Distribution Channel
  - 9.5.7.3.4. Market size and forecast, by End User
  - 9.5.7.3.5. Market size and forecast, by Prescription Type
  - 9.5.7.4. Rest of LAMEA
  - 9.5.7.4.1. Market size and forecast, by Type
  - 9.5.7.4.2. Market size and forecast, by Base
  - 9.5.7.4.3. Market size and forecast, by Distribution Channel
  - 9.5.7.4.4. Market size and forecast, by End User
  - 9.5.7.4.5. Market size and forecast, by Prescription Type

CHAPTER 10: COMPETITIVE LANDSCAPE

10.1. Introduction
10.2. Top winning strategies
10.3. Product mapping of top 10 player
10.4. Competitive dashboard
10.5. Competitive heatmap
10.6. Top player positioning, 2022

CHAPTER 11: COMPANY PROFILES

11.1. Bayer AG
- 11.1.1. Company overview
- 11.1.2. Key executives
- 11.1.3. Company snapshot
- 11.1.4. Operating business segments
- 11.1.5. Product portfolio
- 11.1.6. Business performance
11.2. Bliss GVS Pharma Ltd
- 11.2.1. Company overview
- 11.2.2. Key executives
- 11.2.3. Company snapshot
- 11.2.4. Operating business segments
- 11.2.5. Product portfolio
- 11.2.6. Business performance
11.3. Viatris Inc.
- 11.3.1. Company overview
- 11.3.2. Key executives
- 11.3.3. Company snapshot
- 11.3.4. Operating business segments
- 11.3.5. Product portfolio
- 11.3.6. Business performance
11.4. Church & Dwight Co. Inc.
- 11.4.1. Company overview
- 11.4.2. Key executives
- 11.4.3. Company snapshot
- 11.4.4. Operating business segments
- 11.4.5. Product portfolio
- 11.4.6. Business performance
11.5. Glenmark Pharmaceuticals Limited
- 11.5.1. Company overview
- 11.5.2. Key executives
- 11.5.3. Company snapshot
- 11.5.4. Operating business segments
- 11.5.5. Product portfolio
- 11.5.6. Business performance
11.6. Intas Pharmaceuticals Ltd.
- 11.6.1. Company overview
- 11.6.2. Key executives
- 11.6.3. Company snapshot
- 11.6.4. Operating business segments
- 11.6.5. Product portfolio
11.7. Cadila Healthcare Ltd
- 11.7.1. Company overview
- 11.7.2. Key executives
- 11.7.3. Company snapshot
- 11.7.4. Operating business segments
- 11.7.5. Product portfolio
- 11.7.6. Business performance
- 11.7.7. Key strategic moves and developments
11.8. Novartis AG
- 11.8.1. Company overview
- 11.8.2. Key executives
- 11.8.3. Company snapshot
- 11.8.4. Operating business segments
- 11.8.5. Product portfolio
- 11.8.6. Business performance
11.9. Pfizer Inc.
- 11.9.1. Company overview
- 11.9.2. Key executives
- 11.9.3. Company snapshot
- 11.9.4. Operating business segments
- 11.9.5. Product portfolio
- 11.9.6. Business performance
11.10. Sanofi S.A.
- 11.10.1. Company overview
- 11.10.2. Key executives
- 11.10.3. Company snapshot
- 11.10.4. Operating business segments
- 11.10.5. Product portfolio
- 11.10.6. Business performance

医薬坐剤市場：タイプ別、基剤別、流通チャネル別、エンドユーザー別、処方タイプ別：2023年～2032年の世界機会分析と産業予測

Pharmaceutical Suppositories Market By Type, By Base, By Distribution Channel, By End User, By Prescription Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬坐剤市場：タイプ別

第5章医薬坐剤市場：基剤別

第6章医薬坐剤市場：流通チャネル別

第7章医薬坐剤市場：エンドユーザー別

第8章医薬坐剤市場：処方タイプ別

第9章医薬坐剤市場：地域別

第10章競争情勢

第11章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Base

By End User

By Distribution Channel

By Prescription Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE

CHAPTER 5: PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE

CHAPTER 6: PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER

CHAPTER 8: PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE

CHAPTER 9: PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION

CHAPTER 10: COMPETITIVE LANDSCAPE

CHAPTER 11: COMPANY PROFILES

医薬坐剤市場：タイプ別、基剤別、流通チャネル別、エンドユーザー別、処方タイプ別：2023年～2032年の世界機会分析と産業予測

Pharmaceutical Suppositories Market By Type, By Base, By Distribution Channel, By End User, By Prescription Type : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 医薬坐剤市場：タイプ別

第5章 医薬坐剤市場：基剤別

第6章 医薬坐剤市場：流通チャネル別

第7章 医薬坐剤市場：エンドユーザー別

第8章 医薬坐剤市場：処方タイプ別

第9章 医薬坐剤市場：地域別

第10章 競争情勢

第11章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Base

By End User

By Distribution Channel

By Prescription Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE

CHAPTER 5: PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE

CHAPTER 6: PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER

CHAPTER 8: PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE

CHAPTER 9: PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION

CHAPTER 10: COMPETITIVE LANDSCAPE

CHAPTER 11: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医薬坐剤市場：タイプ別

第5章医薬坐剤市場：基剤別

第6章医薬坐剤市場：流通チャネル別

第7章医薬坐剤市場：エンドユーザー別

第8章医薬坐剤市場：処方タイプ別

第9章医薬坐剤市場：地域別

第10章競争情勢

第11章企業プロファイル